

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7679638

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST	
CONVEYING PARTY DATA		
	Name	Execution Date
	U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION	11/30/2022
RECEIVING PARTY DATA		
Name:	CLARUS THERAPEUTICS, INC.	
Street Address:	55 SKOKIE BLVD., SUITE 340	
City:	NORTHBROOK	
State/Country:	ILLINOIS	
Postal Code:	60062	
PROPERTY NUMBERS Total: 22		
Property Type	Number	
Patent Number:	8241664	
Patent Number:	8492369	
Patent Number:	10543219	
Patent Number:	8778916	
Patent Number:	8778917	
Patent Number:	8828428	
Patent Number:	10245273	
Patent Number:	11179402	
Application Number:	16183155	
Application Number:	15723955	
Application Number:	15723976	
Application Number:	16656178	
Application Number:	15381430	
Application Number:	16656157	
Application Number:	16656169	
Application Number:	16360583	
Application Number:	16382835	
Application Number:	16720183	
Application Number:	16720194	
Application Number:	62833189	

PATENT

Property Type	Number
Application Number:	16274968
Application Number:	16295427

CORRESPONDENCE DATA

Fax Number: (858)509-4010

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8585094071

Email: docket_ip@pillsburylaw.com, michelle.mehok@pillsburylaw.com, sandra.edge@pillsburylaw.com

Correspondent Name: MICHELLE L. MEHOK

Address Line 1: 11682 EL CAMINO REAL, SUITE 200

Address Line 4: SAN DIEGO, CALIFORNIA 92130

ATTORNEY DOCKET NUMBER:	044350.0000011
NAME OF SUBMITTER:	MICHELLE MEHOK
SIGNATURE:	/michelle mehok/
DATE SIGNED:	12/06/2022

Total Attachments: 10

- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page1.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page2.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page3.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page4.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page5.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page6.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page7.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page8.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page9.tif
- source=Clarus - Release of Security Interest in Patent Collateral - Execution Version#page10.tif

RELEASE OF SECURITY INTEREST IN CERTAIN PATENT COLLATERAL

This Release of Security Interest in Certain Patent Collateral is made and effective as of November 30, 2022 by U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as successor to U.S. Bank National Association, in its capacity as Trustee and Collateral Agent pursuant to the Indenture (as defined hereinafter) (in such capacity, the “Collateral Agent”) in favor of CLARUS THERAPEUTICS, INC., a Delaware corporation, the Grantor party to the Patent Collateral Agreement (as defined hereinafter) (the “Grantor”). Capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Indenture, the Collateral Agreement or the Patent Collateral Agreement, as applicable.

WHEREAS, reference is hereby made to that certain Indenture, dated as of March 12, 2020, supplemented by (i) that certain Supplemental Indenture No. 1 dated as of May 27, 2021, (ii) that certain Supplemental Indenture No. 2 dated as of September 9, 2021 and (iii) that certain Supplemental Indenture No. 3 dated as of September 28, 2021 (as amended, modified, renewed, extended or amended, restated, or replaced from time to time, the “Indenture”) by and among the Grantor, U.S. Bank National Association, in its capacity as Trustee and Collateral Agent;

WHEREAS, pursuant to (i) that certain Collateral Agreement dated as of March 12, 2020 (as amended, modified, renewed, extended or amended, restated, or replaced from time to time, the “Collateral Agreement”), by and among the Grantor and certain other grantors from time to time party thereto and the Collateral Agent; and (ii) that certain Patent Collateral Agreement dated as of March 12, 2020 (as amended, modified or amended and restated from time to time, the “Patent Collateral Agreement”), by the Grantor in favor of the Collateral Agent and recorded by the Patent Division of the United States Patent and Trademark Office on March 12, 2020, at Reel 052099 and Frame 0349, Grantor granted to the Collateral Agent for the ratable benefit of the Secured Parties a security interest in all of its right, title and interest in, to and under the Patent Collateral (as defined in the Patent Collateral Agreement); and

WHEREAS, in connection with the sale of certain assets, Grantor has requested that the Collateral Agent hereby terminate, release and discharge fully its security interest in and liens on the portion of the Patent Collateral listed on Schedule I attached hereto as herein provided.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent (in its capacity as such on behalf of the Secured Parties) hereby agrees as follows:

1. Release of Security Interest. The Collateral Agent, without representation or warranty of any kind, hereby (i) (a) terminates, discharges, cancels and releases all of its continuing security interest in and lien on all of the Patent Collateral listed in Schedule I arising under the Collateral Agreement and the Patent Collateral Agreement, (b) re-transfers, re-conveys and re-assigns to Grantor, any and all right, title and interest that the Collateral Agent or any Secured Party may have in or to such Patent Collateral, and (c) acknowledges and agrees that it and the Secured Parties have no further interests in such Patent Collateral, (ii) agrees that it shall, at the sole cost and expense of Grantor, execute all other documents and do all other acts reasonably

requested by Grantor to effect the release of such rights to Grantor; and (iii) authorizes and requests that the United States Patent and Trademark Office note and record this Release of Security Interest in Certain Patent Collateral and any other filings necessary to evidence the release and termination of the Collateral Agent's rights under such Patent Collateral.

2. Governing Law. THIS RELEASE SHALL BE GOVERNED BY CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW) EXCEPT TO THE EXTENT THAT LOCAL LAW GOVERNS THE CREATION, PERFECTION, PRIORITY OR ENFORCEMENT OF SECURITY INTERESTS.


3. Counterparts. This Release of Security Interest in Certain Patent Collateral may be executed in any number of counterparts, all of which taken together shall constitute one agreement, and any of the parties hereto may execute this Release by signing any such counterpart, and a copy of any such counterpart shall be valid as an original.

4. Concerning the Collateral Agent. It is expressly understood and agreed that U.S. Bank National Association is entering into this Release solely in its capacity as Collateral Agent as appointed pursuant to the Indenture and shall be entitled to all of the rights, privileges, immunities and protections under the Indenture as if such rights, privileges, immunities and protections were set forth herein.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has executed this Release of Security Interest in Certain Patent Collateral as of the day and year first above written.

U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee and Collateral Agent



By: _____

Name: Diana Jacobs

Title: Vice President

[Signature Page to Release of Security Interest in Certain Patent Collateral]

4858-8515-3343.v6

PATENT
REEL: 062000 FRAME: 0056

SCHEDULE I
PATENT COLLATERAL

<i>Country</i>	<i>Title</i>	<i>Application No./Application Date</i>	<i>Registration No./Registration Date</i>	<i>Case Status</i>
US	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	11/911,446 11/12/2007	8,241,664 08/14/2012	Issued
US	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	12/758,770 04/12/2010	8,492,369 07/23/2013	Issued
US	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	15/723,985 10/03/2017	10,543,219 01/28/2020	Issued
US	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	13/584,958 08/14/2012	8,778,916 07/15/2014	Issued
US	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	14/026,655 09/13/2013	8,778,917 07/15/2014	Issued
US	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	14/254,545 04/16/2014	8,828,428 09/09/2014	Issued
US	Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents	15/107,492 06/23/2016	10,245,273 04/02/2019	Issued
US	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	15/814,162 11/15/2017	11,179,402 11/23/2021	Issued
US	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	16/183,155 11/07/2018	n/a	Pending
US	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	15/723,955	n/a	Abandoned

Schedule I to Release of Security Interest in Certain Patent Collateral

<i>Country</i>	<i>Title</i>	<i>Application No./Application Date</i>	<i>Registration No./Registration Date</i>	<i>Case Status</i>
	compositions comprising same	10/03/2017		
US	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	15/723,976 10/03/2017	n/a	Abandoned
US	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	16/656,178/ 10/17/2019	11,331,325 5/17/2022	Issued
US	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	15/381,430 12/16/2016	10,617,696 4/14/2020	Issued
US	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	16/656,157 10/17/2019	11,179,403 11/23/2021	Issued
US	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	16/656,169 10/17/2019	11,426,416 8/30/2022	Issued
US	Methods of treating testosterone deficiency	16/360,583 03/21/2019	n/a	Abandoned
US	Methods of treating testosterone deficiency	16/382,835 04/12/2019	n/a	Pending
US	Methods of treating testosterone deficiency	16/720,183 12/19/2019	n/a	Abandoned
US	Methods of treating testosterone deficiency	16/720,194 12/19/2019	n/a	Abandoned

Schedule I to Release of Security Interest in Certain Patent Collateral

<i>Country</i>	<i>Title</i>	<i>Application No./Application Date</i>	<i>Registration No./Registration Date</i>	<i>Case Status</i>
US	Oral pharmaceutical products and methods of use combining testosterone esters with anti-hypertensive agents	62/833,189 04/12/2019	n/a	Expired
US	Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents	16/274,968 02/13/2019	n/a	Pending
US	Methods of treating testosterone deficiency	16/295,427 03/07/2019	n/a	Pending
Australia	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	2006236564 04/14/2006	2006236564 06/02/2011	Issued
Australia	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	2011201422 03/29/2011	2011201422 9/2/2012	Issued
Australia	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	2010351080 4/12/2010	2010351080 12/11/2014	Issued
Australia	Methods of treating testosterone deficiency	2014232911 3/17/2014	2014232911 1/5/2017	Issued
Australia	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	2014265072 11/20/2014	2014265072 1/5/2017	Issued
Brazil	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	20067549 4/14/2006	n/a	Pending
Brazil	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	112012025961 4/12/2010	112012025961 6/15/2021	Issued
Canada	Pharmaceutical Delivery Systems for Hydrophobic Drugs	2,604,943	2,604,943	Issued

Schedule I to Release of Security Interest in Certain Patent Collateral

<i>Country</i>	<i>Title</i>	<i>Application No./Application Date</i>	<i>Registration No./Registration Date</i>	<i>Case Status</i>
	and Compositions Comprising Same	4/14/2006	9/17/2013	
Canada	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	2,795,908 4/12/2010	2,795,908 10/13/2015	Issued
Canada	Methods of Treating Testosterone Deficiency	2,905,703 3/17/2014	n/a	Pending
China	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	201080066142.8 4/12/2010	102883710 9/10/2014	Issued
China	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	20141000576.4 1/6/2014	103705462 8/31/2016	Issued
Costa Rica	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	CR2012-000535 4/12/2010	20120535A 4/24/2018	Issued
Europe	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	10714521.1 4/12/2010	EP2558073B1 9/10/2014	Issued
Europe	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	14179390.1 4/12/2010	EP 2803350 9/20/2017	Issued
European Patent Convention	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	15165073.6 4/24/2015	n/a	Pending
European Patent Convention	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	15186752.0 4/14/2006	2985026 8/3/2022	Issued
European Patent Convention	Methods of Treating Testosterone Deficiency	14765688.8 3/17/2014	n/a	Pending

Schedule I to Release of Security Interest in Certain Patent Collateral

<i>Country</i>	<i>Title</i>	<i>Application No./Application Date</i>	<i>Registration No./Registration Date</i>	<i>Case Status</i>
Hong Kong	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	13107867.0 7/5/2013	HK1180593 12/19/2014	Issued
Hong Kong	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	14109461.5 9/19/2014	1196765 7/28/2017	Issued
India	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	4053/KOLNP/2007 4/14/2006	266487 5/11/2015	Issued
India	Oral Testosterone Ester Formulations	2012DN9522 4/12/2010	324236 10/31/2019	Issued
Indonesia	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	WO0201204598 4/12/2010	IDP000040238 12/3/2015	Issued
Israel	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	222315 4/12/2010	222315 11/1/2017	Issued
Japan	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	2008-506780 4/14/2006	5887044 2/19/2016	Issued
Japan	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	201326993 4/14/2006	5778705 7/17/2015	Issued
Japan	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	2015216911 11/4/2015	6251713 12/1/2017	Issued
Japan	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	2013504871 4/12/2010	5992397 8/26/2016	Issued
Japan	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	201547645 3/10/2015	5815900 10/2/2015	Issued
Japan	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	2015184441 9/17/2015	6097803 2/24/2017	Issued

Schedule I to Release of Security Interest in Certain Patent Collateral

<i>Country</i>	<i>Title</i>	<i>Application No./Application Date</i>	<i>Registration No./Registration Date</i>	<i>Case Status</i>
Korea, Republic of	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	1020137026909 4/1/2006	101382725 8/21/2014	Issued
Korea, Republic of	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	1020137028305 10/25/2013	101432466 8/13/2014	Issued
Korea, Republic of	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	1020127027383 4/12/2010	101460871 11/11/2014	Issued
Korea, Republic of	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	20147001158 1/15/2014	101607034 3/28/2016	Issued
Mexico	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	MX/a/2012/011952 4/12/2010	328628B 3/19/2015	Issued
Mexico	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	MX/a/2015/003139 3/11/2015	352328 11/21/2017	Issued
New Zealand	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	602821 4/12/2010	602821 10/29/2014	Issued
Patent Cooperation Treaty	Methods of Treating Testosterone Deficiency	PCT/US2019/067326 12/19/2019	n/a	Expired
Philippines	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	1-2012-502016 4/12/2010	1-2012-502016 3/5/2015	Issued
Russian Federation	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	2007142204 4/14/2006	2429850 9/27/2011	Issued
Russian Federation	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	2015112862 4/8/2015	2642244 1/24/2018	Issued

Schedule I to Release of Security Interest in Certain Patent Collateral

<i>Country</i>	<i>Title</i>	<i>Application No./Application Date</i>	<i>Registration No./Registration Date</i>	<i>Case Status</i>
Russian Federation	Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same	2011119796 5/17/2011	2623206 6/22/2017	Issued
Singapore	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	2012075305 4/12/2010	184540 4/24/2015	Issued
South Africa	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	2012/07517 4/12/2010	2012/07517 6/26/2013	Issued

Schedule I to Release of Security Interest in Certain Patent Collateral

4858-8515-3343 v6

PATENT

REEL: 062000 FRAME: 0063

RECORDED: 12/06/2022